Meningitis Diagnostic Testing Market Size, Share and Analysis by Test Type (Latex Agglutination Test, PCR Assay, Lateral Flow Assay Test, Others), By Causative Agents (Bacteria, Virus, Fungi, Others), By End User (Hospitals, Diagnostic Centres, Academic and Research Institutes) and Regional Forecast, 2025-2032

The global meningitis diagnostic testing market size was valued at USD 129.45 million in 2025. The market is projected to grow from USD 134.59 million in 2026 to USD 183.75 million by 2034, exhibiting a CAGR of 3.97% during the forecast period.

Meningitis is an inflammation of membranes called meninges surrounding the brain and spinal cord. Mby viral, bacterial, parasitic and fungal infections. Meningitis has emerged as an area of global concern owing to its potential for causing an epidemic and hence, there is active government support to eradicate meningitis by establishing sophisticated diagnostic centers and hospitals to treat patients.

The diagnosis of meningitis are performed using either rapid latex agglutination test or by using highly advanced equipment for PCR, immunoassays, and others.

To gain extensive insights into the market, Download for Customization

The global is estimated to register a higher CAGR during the forecast period owing to factors such as high prevalence of meningitis, rise in demand for rapid diagnosis by using innovative technologies, increase in number of diagnostic centers and active government support to control meningitis disease outbreaks. However, lack of is a major factor restraining the growth of global meningitis diagnostic testing market during the forecast period.

Key Players Covered

The major companies in the global meningitis diagnostic testing market report include Siemens Healthcare GmbH, BioFire Diagnostics, Thermo Fisher Scientific Inc., Luminex Corporation, IMMY, Bio-Rad Laboratories Inc., Seegene Inc., and other players.

SEGMENTATION

Key Insights

• Epidemiology of Meningitis, by Key Regions/Countries
• Prevalence of Meningitis, by Key Regions/Countries 2018
• Comparative Overview of Key Test Available for Meningitis Diagnosis
• Key Mergers and Acquisitions

Regional Analysis

The global meningitis diagnostic testing market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America followed by Europe accounted for largest share of the global meningitis diagnostic testing market in 2018. Asia Pacific is projected to grow at a faster pace due to the increasing patient awareness and developing healthcare infrastructure. In Middle East & Africa, the meningitis diagnostic testing market is anticipated to have an exponential growth due to the outbreak of meningitis in Sub-Saharan Africa. According to the World Health Organisation (WHO), the prevalence of meningitis is highest in regions from Senegal to Ethiopia, with approximately 30,000 cases reported each year and is considered as the “meningitis belt” of sub-Saharan Africa. These trends are attributed to fuel the demand for meningitis diagnosis in these regions. In Latin America meningitis is considered as a serious health concern and the meningitis diagnostic testing market is expected to project a moderate growth during the forecast period.

Meningitis Diagnostic Testing Industry Developments

• In January 2018, Siemens Healthineers announced the completion of acquisition of Fast Track Diagnostics with an aim to offer efficient molecular testing assays for diagnosis of infectious disease like meningitis.
• In March 2018, researchers at the University’s Institute of Infection and Global Health with the help of Fast Track Diagnostics announced that they were developing a new commercial blood test to improve the diagnosis and management of patients suspected with meningitis.
• In 2017, researchers at Queen’s University in partnership with the Belfast Trust developed a diagnostic test, known as LAMP (Loop Mediated Isothermal Amplification), which is capable to diagnose meningitis disease within an hour.